In the news
In the news
Press Releases
Press coverage of Leaps and portfolio companies
Leaps events
Spotlight on Juergen Eckhardt
Juergen Eckhardt is EVP and Head of Leaps by Bayer, the strategic investment unit of Bayer AG, and Head of Business Development, & Licensing (BD&L) for the Pharmaceuticals division. He is a medical doctor and venture investor in healthcare, biotech, and agriculture with more than 20 years of experience. He is a strong believer that scientific breakthroughs can help us overcome huge challenges, including to cure and prevent chronic disease and to feed an ever-growing world population in a sustainable way – in short: science for a better life. He holds an MD from the University of Basel, Switzerland, and an MBA from INSEAD in Fontainebleau, France.
Read More
Op-eds by Juergen Eckhardt
Reports
Explore the latest reports and publications developed by Leaps by Bayer and our collaborators.
Read about our 2025 milestones, portfolio company highlights, engagement activities, and more.
Download
Find out how different generations worldwide feel about breakthrough science in our snapshot report 'How Society Feels About Breakthrough Science: Findings Across Generations’, a collaboration with BCG and market research by IPSOS.
Download
Find out how people in the US feel about breakthrough science in our Breakthrough Study Snapshot Report, a collaboration with BCG and market research by IPSOS.
Download
Press Kit
Leaps by Bayer is the strategic investment unit of Bayer AG. We invest in teams pursuing fundamental breakthroughs in life science, targeting huge challenges across health and agriculture.
Some call them impossible. We call them “Leaps”.
Media Contact
Kira Peikoff
Kira Peikoff is a former journalist who covered emerging biotechnologies for publications including The New York Times, Newsweek, and Popular Mechanics. She now leads communications for Leaps by Bayer.
Our return to humanity
The Leaps team brings together a diverse group of individuals with expertise in biotech, healthcare, agriculture, investment, and communication.
